ABL1 is altered in 0.87% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

ABL1 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains ABL1 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

AFF1 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains AFF1 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ALK is altered in 5.28% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

ALK is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ARID1A is altered in 4.66% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

ARID1A is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ATM is altered in 4.64% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

ATM is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ATR is altered in 2.72% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

ATR is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ATRX is altered in 1.47% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

ATRX is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ATRX status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BAP1 is altered in 0.29% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

BAP1 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BARD1 is altered in 1.01% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

BARD1 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BCL2 is altered in 0.6% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

BCL2 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BCL2 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BCL6 is altered in 2.35% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

BCL6 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BCR is altered in 1.32% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

BCR is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains BCR status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

BRCA1 is altered in 1.47% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

BRCA1 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BRCA2 is altered in 3.78% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

BRCA2 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BRIP1 is altered in 1.18% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

BRIP1 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRIP1 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

C11orf30 is altered in 7.69% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

C11orf30 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains C11orf30 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CDK12 is altered in 1.81% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

CDK12 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CHEK1 is altered in 1.02% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CHEK2 is altered in 1.76% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

DEK is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains DEK status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ELL is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains ELL status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ERCC2 is altered in 1.2% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

ERCC2 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC2 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ERCC3 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC3 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ERCC4 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC4 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ERCC5 is altered in 1.24% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

ERCC5 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC5 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ERCC6 is altered in 1.41% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

ERCC6 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC6 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCA is altered in 2.94% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

FANCA is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCA status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCB is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCB status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCC is altered in 0.59% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

FANCC is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCD2 is altered in 1.37% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

FANCD2 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCE is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCF is altered in 1.57% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

FANCF is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCF status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCG is altered in 0.8% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

FANCG is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCG status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCI is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCI status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCL is altered in 1.41% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

FANCL is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCM is altered in 1.56% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

FANCM is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCM status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FGFR3 is altered in 1.45% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FLT3 is altered in 2.03% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

FLT3 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

HDAC1 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HDAC1 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

HDAC2 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HDAC2 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

IGH is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IGH status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

KMT2A is altered in 3.2% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

KMT2A is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2A status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MAF is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MAF status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAFB is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MAFB status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MDM2 is altered in 0.59% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

MDM2 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MDM4 is altered in 0.29% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MECOM is altered in 5.6% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

MECOM is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MECOM status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MLF1 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MLF1 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MLH1 is altered in 0.59% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

MLH1 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MLH3 is altered in 1.47% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

MLH3 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MLH3 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MLLT1 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MLLT1 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT10 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MLLT10 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT3 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MLLT3 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT4 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MLLT4 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MRE11A is altered in 1.7% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

MRE11A is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MSH2 is altered in 0.88% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

MSH2 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MSH2 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MSH3 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MSH6 is altered in 1.17% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

MSH6 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MUTYH is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MUTYH status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYC is altered in 1.76% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

MYC is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

NBN is altered in 0.3% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

NBN is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NBN status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

NPM1 is altered in 1.17% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

NPM1 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

NRIP3 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains NRIP3 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NUP214 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains NUP214 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PALB2 is altered in 0.88% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

PALB2 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PARP1 is altered in 0.45% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

PARP1 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PARP2 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PBX1 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains PBX1 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PMS1 is altered in 1.21% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

PMS1 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PMS1 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PMS2 is altered in 0.6% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

PMS2 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

POLD1 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains POLD1 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

POLE is altered in 1.65% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

POLE is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains POLE status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

POLQ is altered in 7.35% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

POLQ is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains POLQ status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PPP2R1A is altered in 0.34% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

PPP2R1A is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PPP2R1A status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PPP2R2A is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PPP2R2A status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PRKDC is altered in 5.13% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

PRKDC is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PRKDC status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD50 is altered in 1.35% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

RAD50 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51 is altered in 0.59% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

RAD51 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51B is altered in 0.62% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

RAD51B is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51C is altered in 0.34% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

RAD51C is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51C status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51D is altered in 0.34% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

RAD51D is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD54L is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains RPN1 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SLX4 is altered in 4.23% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

SLX4 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains SLX4 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

SMARCB1 is altered in 2.62% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

SMARCB1 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

STAG2 is altered in 0.88% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

STAG2 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains STAG2 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

STK11 is altered in 2.62% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

STK11 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains STK11 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

TCF3 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains TCF3 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TP53 is altered in 12.43% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

WHSC1 is altered in 1.23% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

WHSC1 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains WHSC1 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

XRCC1 is altered in 1.56% of mature T-cell and NK-cell non-hodgkin lymphoma patients [2].

XRCC1 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains XRCC1 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].